Heart Disease Risk Skyrockets in Trans People Taking Hormones, Study Finds

The cross-sex hormone therapies Democrats and other leftists want to make sure youths can access aren’t just deformative and destabilizing, but deadly.

A new study published in the European Journal of Endocrinology revealed that male transvestites taking feminizing hormones are 93% more likely to suffer heart disease than other men. Female transvestites taking testosterone are 63% more likely to suffer heart disease than other women.

Lead author Dr. Dorte Glintborg of Denmark’s Odense University Hospital noted in a 2021 study that “epidemiological studies in transgender women reported increased risk of acute myocardial infarction and stroke during feminizing treatment, whereas long-term, controlled studies regarding feminizing treatment and risk of arterial CVD are lacking.”

In an apparent follow-up last month, Glintborg determined that male transvestites taking cross-sex hormones were nearly twice as likely to suffer from any cardiovascular disease as men not taking hormones, reported the Telegraph.

While men are especially at risk, all individuals undergoing cross-sex conversion therapy face “significantly increased risk” of heart attacks, strokes, high blood pressure, and high cholesterol levels.

Glintborg and her team reportedly tracked the health of 2,671 transvestites from Denmark — 1,270 of whom were women and 1,402 of whom were men — over a five-year period. The average age for the men was 26 and the average age for the women in the study was 22. Over 1,000 appear to have undergone a legal sex change.

Relative to the incidence of heart disease in a control group of 26,700 people, male transvestites taking estrogen were 93% more likely to suffer the ailment than men not on feminizing hormones and 73% more likely to suffer the ailment than women.

On the flip side, women taking testosterone were found to be 63% more likely than women not taking the hormone and twice as likely as men to develop some form of heart disease.

“Cardiovascular and metabolic outcomes were more prevalent in transgender persons compared to controls. Gender-affirming hormone therapy exposure could contribute to the elevated cardiovascular risk in transgender men, assigned female at birth,” the researchers concluded. “Future studies will be able to bring further knowledge regarding mechanisms for higher cardiovascular risk in transgender men and women.”

Glintborg, who runs her hospital’s endocrinology department, presented her findings this week at the Annual Meeting of the European Association for the Study of Diabetes.

She noted a possible silver lining for female transvestites, stating, “While increased rates of cardiovascular disease might normally go hand-in-hand with increased rates of diabetes, for trans men (assigned female at birth AFAB), use of testosterone usually increases lean body mass and this could be protecting against an increased risk of diabetes,” reported Medical Xpress.

Conversely, for male transvestites, “hormone treatments such as estrogen will increase fat mass and lower lean body mass, and increased estrogen is usually associated with increased risk of autoimmune disease and inflammation,” said Glintborg, adding, “Some studies found a higher risk of type 2 diabetes in transgender women, but this could not be confirmed by others.”